Member Info for PM2022

You can explain it to Kevin not to me.

Placing is all you can mention the last 4 years. So boring it puts me to sleep. Learn to make some money from your investments first.

Porky foolish you are. Ever wondered what the real Kevin can really do to you? What a fool. Be careful as he will not want his name slandered in such a way and you will have nowhere to run.

He tried to make himself look better by pretending to make money on GDR lol. Comedian.

That was with the old board and basically not even Valirx. Has no relevance to the current strategy.

The past does not equal the future. The pipeline here has been building but just needs delivery.

NYCT failure

HE1 Failure

DDDD Failure

Inspirit Energy Holdings Failure

GDR Failure

Sabien Tech Failure

HARL Failure

One success Valirx which you bailed out for once but overall a complete disaster. Correct me if I am wrong but from the years that is how I see the list. You are no expert.

Keyboard warrior. Claims to be an expert in all kinds of things from mergers and acquisitions, AIM stocks and what not depending on what the agenda is. What person with a life trolls a stock that they are not invested in day in day out for many years and behaves like a child on a chat board.

401 completion should take this to 5p range with a positive evaluation result. Any discount from that price if they deliver in the next 3 months will likely be minimal given potential for new investors.

We should be good until year end then we can see where we are with 201, 401, interviews and projects to be completed before year end.

It is to build a list of potential investors which takes many weeks and months to execute after the event including going inside for a placing etc.

It should kind of indicate we should not get a placing the coming weeks perhaps early 2025 but before that plenty of news and a much higher share price.

It would be no surprise if they announced the 401 deal before the presentation. An interesting month to come.

You previously mentioned that Valirx should take on around 10 evaluation projects within a year. Now, you're dissapointed because no new projects have come through recently.

To point out the lack of knowledge you have goes back to the days of DDDD. You want Valirx to be a drugs factor but with no money just like 4D were. Has it ever occurred to you what would happen if they take on so many projects and say 4/10 pass the evaluation phase with each project needing millions. How do you expect Valirx to fund those projects at the preclinical stage within the same cycle? The point is to bring in quality projects but ensure they get at least one project to deal stage so either CLX or one of the others like maybe Imperial and maybe have at least 5-10 million in the bank before trying to build a bigger pipeline. Otherwise they would go bust just like 4D. The alternative was a higher share price therefore a lower dilution and it needed 201 for that. Your level of understanding is below average which is perhaps why they ignore you. Also bringing in rubbish projects which are likely to fail would just mean the share price dropping lower each time a failure happens and wasting money.

I agree on the point of BOD changes as all it has done is slow things down but you were adamant i was wrong and changes were needed but now your going back on that.

EUDA should not be more than 1p imo. Maybe shorters.

I can tell you failed your GCSE maths.

If even you are admitting they have 750k left and are burning 200k a month how does that equate to early October. Foolish.

No settlements to pay. Talking nonsense.

Agree Fred. It would make little sense given they are invested. They would get wiped out without really trying and no chance they would have run out of cash already with plenty of news scheduled

for this year. Therefore not concerned.

They should at least be able to get this to 4/5p from here.

They need delivery to sell a placing and not just empty promises so highly unlikely at the moment.

I think we will get a few big outcomes and several interviews before that happens. Projections suggested the end of Q1 without lab revenue but I think they would have been careful how cash has been spent so I would think that the end of q1 2025 should be fair.

Surely they must be pushing hard for 401 and 201 or one before year end as anticipated along with lab contracts and maybe an SPV coming through with maybe a few interviews.

The projection was towards end of q1 2025 so if the new BOD were doing a good job they would have been preserving the cash as much as possible so that either 201 or 401 gets over the line first with hopefully some positive evaluation projects. A collection of lab contracts extends that timeframe.

Thing is Porky will keep extending his deadline every month until it happens like he always does. It will eventually happen but I suspect at a much higher price and after some significant news and likely early 2025.

Maybe a 20/25% discount from 5p and upwards after very significant news. It all depends on the delivery.

I would perhaps worry about that in December but not now.

Signing 401 will allow a good placing price imo as only one trail is needed for 15 million plus royalties which can be done fairly quickly within 18 months hopefully. 201 obviously means much more cash and a share price multiples of this. Look at EUDA share price clearly they must be confident.

It doesn't need me but just pointing out that we likely will have lots of news before that comes with what appears to be plenty of time left.

From the RNS last year:

Whilst the in vivo study did not achieve the desired level of anti-cancer activity, it demonstrated no adverse toxicity leading to the conclusion that further research around this molecular series would be beneficial.

It probably needs a fair amount of work to show anti-cancer activity so maybe it is ongoing and the overall agreement is for much longer. Based on the last presentation it looks like the other projects will likely produce better outcomes within the timeframe until one of the compounds at Barcelona shows promise.

The potential of 11 lab contracts was stated in the RNS so clearly the lab should be generating decent revenue with more contracts due.

Whilst that is happening the cash runway will keep being extended hopefully to mid 2025. Logically speaking we should get significant news relating to the conclusion of 201,401 or both. Add in lab contracts and evaluation project outcomes.

Anyone with any brains would know they have to sell it first. So significant upside potential from here first in my opinion.

I would think they would have put cost cutting measures in over the last few months so well into 2025 is a fair bet with lots of news first.

Stick to the facts:

Cash runway now appears sufficient to carry it well into 2025

Full year 2023E Group net losses along with the cost of establishing/facilitating Inaphaea Biolabs (including the

acquisition of Imagen Therapeutics), resulted in an average estimated cash burn of a little over £200,000/month for

the period. If one now prudently assumes further, albeit somewhat reduced, Group net losses for 2024E, during

which time it utilises the newly raised net funding to accelerate exploitation and integration of its acquired BioBank

materials in tandem with commercial development/brand establishment within Inaphaea while also advancing

its preclinical product pipeline in the absence of further cash acquisition(s), the Group now appears to have runway

sufficient to carry it into Q2 2025.

Between now and then, of course, various upside scenarios suggest this period could become significantly extended.

This could be derived through securing higher volumes of fee-paying service customers for Inaphaea, potential

signing of licensing agreements with external parties willing to pay upfront charges and fund ongoing

development of the Group’s preclinical and/or clinical assets which, in turn, could also attract continuing

milestones instalments. Any such outcome could be both transformative for ValiRx’s balance sheet while also

proving its business model.

If you are talking to me I would say forget Barcelona.

I think Cathy mentioned Stingyray as one of the most promising projects and news due in the next month or so. Plus 401 or 201 and I think they will be working to target to get some lab contracts before they consider asking for more money.

Also she mentioned previously that Imperial would take 6-12 months so we could get that soon and that is at a much later stage than the rest.

A busy few months I think in terms of newsflow. We shall see.